Celgene Corp. (CELG)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Difficulty: Beginner

Celgene Corp., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

		Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Short-term borrowings and current portion of long-term debt
	Accounts payable
	Accrued expenses and other current liabilities
	Income taxes payable
	Current portion of deferred revenue
	Current liabilities
	Deferred revenue, net of current portion
	Income taxes payable
	Deferred income tax liabilities
	Other non-current tax liabilities
	Other non-current liabilities
	Long-term debt, net of discount, excluding current portion
	Non-current liabilities
	Total liabilities
	Preferred stock, $.01 par value per share; none outstanding
	Common stock, $.01 par value per share
	Common stock in treasury, at cost
	Additional paid-in capital
	Retained earnings
	Accumulated other comprehensive income (loss)
	Stockholders’ equity
	Total liabilities and stockholders’ equity

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Celgene Corp.’s current liabilities as a percentage of total liabilities and stockholders’ equity declined from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.
Non-current liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Celgene Corp.’s non-current liabilities as a percentage of total liabilities and stockholders’ equity declined from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Celgene Corp.’s total liabilities as a percentage of total liabilities and stockholders’ equity declined from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.
Stockholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Celgene Corp.’s stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.

	Celgene Corp.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Celgene Corp. (CELG)

Common-Size Balance Sheet: Liabilities and Stockholders’ EquityQuarterly Data

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data